Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-02-11
2009-12-22
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387900, C530S388100
Reexamination Certificate
active
07635759
ABSTRACT:
A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab) or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells.
REFERENCES:
patent: 4816402 (1989-03-01), Rosen et al.
patent: 5728819 (1998-03-01), Jacobs et al.
Oppenheim et al, 1985, J. Biol. Chem. vol. 260, pp. 10671-10679.
Voet et al, 1990, Biochemistry, John Wiles & Sons, p. 1102 only.
Banner et al., “Application of Monoclonal Antibody 44-3A6 in the Cytodiagnosis and Classification of Pulmonary Carcinomas,”Diagnostic Cytopathology, 1 (4): 300-307 (1985).
Bentz et al., “Expression of the Adenocarcinoma-related Antigen Recognized by Monoclonal Antibody 44-3A6 in Salivary Glandneoplasias,”Head and Neck Surgery, 118 (5): 603-609 (1988).
Cajulis et al., “Monoclonal Antibody 44-3A6 as an Adjunct in Cytdiagnosis of Adenocarcinomas in Body Fluids,”Diagnostic Cytopathology, 9 (2): 179-183 (1993).
Combs et al., “Expression of the Antigenic Determinant Recognized by the Monoclonal Antibody 44-3A6 on Select Human Adenocarcinomas and Normal Human Tissues,”Tumor Biology, 9: 116-122 (1988).
Combs et al., “Pleomorphic Carcinoma of the Pancreas with Osteoclast-Like Giant Cells Expressing and Epithelial-Associated Antigen Detected by Monoclonal Antibody 44-3A6,”Diagnostic Cytopathology, 4 (4): 316-322 (1988).
Dinchuk et al., “Aspartyl beta-hydroxylase (Asph) and an evolutionalrily conserved isoform of Asph missing the catalytic domain share exons with junction,”Journal of Biological Chemistry, 275 (50): 39543-39554 (2000).
Duda et al., “Monoclonal Antibody 44-3A6 as a Marker for Breast Carcinoma,”Tumor Biology, 12: 254-260 (1991).
Engelhardt et al., “Early impairment of calcium handling and altered expression of junction in hearts of mice overexpressing the beta 1-adrenergic receptor,”FASEB Journal, 15 (14): 2718-2720 (2001).
Froemming et al., “Native skeletal muscle dihydropyridine receptor exists as a supramolecular triad complex,”Cell. Mol. Life Sci., 58: 312-320 (2001).
Glover et al., “Calsequestrin binds to monomeric and complexed forms of key calcium-handling proteins in native sarcoplasmic reticulum membranes from rabbit skeletal muscle,”Biochimica et Biophysica Acta., 1515 (2): 120-132 (2001).
Gronke et al., “Partial Purification and Characterization of Bovine Liver Aspartyl Beta-hydroxylase,”J. Biol. Chem., 265: 8558-8565 (1990).
Gronke et al., “Aspartyl Beta-hydroxylase: In vitro Hydroxylation of a Synthetic Peptide Based on the Structure of the First Growth Factor-like Domain of Human Factor IX,”Pro. Natl. Acad. Sci. USA, 86: 3609-3613 (1989).
Jia et al., “cDNA Cloning and Expression of Bovine Aspartyl (Asparaginyl) Beta-hydroxylase,”J. Biol. Chem., 267 (20): 14322-14327 (1992).
Jia et al., “A Fully Active Catalytic Domain of Bovine Aspartyl (Asparaginyl) Beta-hydroxylase Expressed inEscherichia coli: Characterization and Evidence for the Identification of an Active-site Region in Vertebrate Alpha-ketoglutarate-dependent Dioxygenases,”Proc. Natl. Acad. Sci. USA, 91: 7227-7231 (1994).
Jones et al., “Purification, primary structure, and immunological characterization of the 26-kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum,”Journal of Biological Chemistry, 270 (51): 30787-30796 (1995).
Jones et al., “Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin.”Journal of Clinical Investigation, 101 (7):1385-1393 (1998).
Kagari et al., “Biochemical characterization of calsequestrin-binding 30-kDa protein in sarcoplasmic reticulum of skeletal muscle,”Biochemical&Biophysical Research Communications, 227 (3): 700-706 (1996).
Kirchhefer et al., “Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1,”Journal of Biological Chemistry, 276 (6): 4142-4149 (2001).
Kiriazis et al., “Genetically engineered models with alterations in cardiac membrane calcium-handling proteins,”Annual Review of Physiology, 62: 321-351 (2000).
Kobayashi et al., “Localization and Characterization of the Calsequestrin-binding Domain of Triadin 1,”Journal of Biological Chemistry, 275 (23): 17639-17646 (2000).
Kobayashi et al., “Identification of triadin 1 as the predominant triadin isoform expressed in mammalian myocardium,”Journal of Biological Chemistry, 274 (40): 28660-28668 (1999).
Kohler et al., “Succinate dehydrogenase b mRNA ofDrosophila melanogasterhas a functional iron-responsive element in its 5′-untranslated region,”Journal of Biological Chemistry, 270 (51): 30781-30786 (1995).
Korioth et al., Genbank Accession No. V03109,Gene, 150(2): (1994).
Korioth et al., “Cloning and characterization of the human gene encoding aspartyl Beta-hydroxylase,”Gene, 150 (2): 395-399 (1994).
Landis et al., “Cancer Statistics, 1998,”Ca. Cancer J. Clin., 48: 6-9 (1998).
Lavaissiere et al., “Overexpression of Human Aspartyl (Asparaginyl) Beta-hydroxylase in Hepatocellular Carcinoma and Cholangiocarcinoma,”J. Cliin. Invest., 98: 1313-1323 (1996).
Lee et al., “Malignant Mesotheliomas: Improved Differential Diagnosis from Lung Adenocarcinomas Using Monoclonal Antibodies 44-3A6 and 624A12,”Amer. J. Path., 98: 497-507 (1986).
Lee et al., “Immunohistochemical Analysis of Human Pulmonary Carcinomas using Monoclonal Antibody 44-3A6,”Cancer Research, 45: 5813-5817 (1985).
Lim et al., “cDNA cloning and characterization of human cardiac junction,”Gene, 255 (1): 35-42 (2000).
Luss et al., “Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species,”Journal of Molecular&Cellular Cardiology, 31 (6):1299-1314 (1999).
Nori et al. “Targeting of calsequestrin to sarcoplasmic reticulum after deletions of its acidic carboxy terminus,”American Journal of Physiology, 277 (5 Pt 1): C974-981 (1999).
Ohlendieck, “Changes in Ca2+-Regulatory Muscle Membrane Proteins During the Chronic Low-Frequency Stimulation Induced Fast-To-Slow Transition Process,”Basic Appl. Myol., 10 (3): 99-106 (2000).
Piehl et al., “Immunohistochemical Identification of Exocrine and Neuroendocrine Subsets of Large Cell Lung Carcinomas,”Path Res. Prac., 183: 675-682 (1988).
Radosevich et al., “Monoclonal Antibody 44-3A6 as a Probe for a Novel Antigen Found on Human Lung Carcinomas with Glandular Differentiation,”Cancer Research, 45: 5805-5812 (1985).
Radosevich et al., “Monoclonal Antibody Assays for Lung Cancer,” In vitroDiagnosis of Human Tumors Using Monoclonal Antibodies, 101-121 (1988).
Radosevich et al., “Immunohistochemical Analysis of Human Adenocarcinomas of the Lung Using the Monoclonal Antibody 44-3A6,”Tumor Biology, 11: 181-188 (1990).
Radosevich et al., “Immunohistochemical Analysis of Differentiation Markers for Non-small-cell Lung Cancer,”Lung Cancer Differentiation. Lung Biology in Health and Disease, 195-216 (1990).
Radosevich et al., “Cell Cycle and Electron Microscopic Evaluation of the Adenocarcinoma Antigen Recognized by the Monoclonal Antibody 44-3A6,
Immvarx, Inc.
Wilson Sonsini Goodrich & Rosati
Yu Misook
LandOfFree
Gene encoding labyrinthin, a marker for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene encoding labyrinthin, a marker for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene encoding labyrinthin, a marker for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4139769